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Purpose: TNM Stage 3B encompasses a wide range of primary tumor and nodal
metastatic tumor burden. This study aimed to evaluate the prognostic value of
quantitative FDG PET/CT parameters in patients with newly diagnosed Stage 3B
Non-Small Cell Lung Cancer (NSCLC).
Materials and Methods: Institutional review board approved retrospective study
identified patients diagnosed with Stage 3B NSCLC (8th edition TNM classification) on
baseline FDG PET/CT at two medical centers (Medical centers A and B), between Feb
2004 and Dec 2014. Patients were excluded if they had prior NSCLC treatment or
recent diagnosis of a second primary cancer. Quantitative FDG PET/CT parameters
including whole body metabolic tumor volume (MTVwb), total lesion glycolysis
(TLGwb), and maximum standardized uptake value (SUVmaxwb) were measured
from baseline PET/CT using Edge method with Mimvista software. The primary
endpoint was overall survival (OS). Cox proportional hazard regression and Kaplan-
Meier overall survival analyses were used to test for an association between OS and
quantitative FDG PET/CT parameters. The distributions of MTVwb, TLGwb, SUVmaxwb
were skewed, so a natural logarithm transformation was applied and the transformed
variables [(ln(MTVwb), ln(TLGwb), and ln(SUVmaxwb)] were used in the analysis.
Results: The training set included 110 patients from center A with Stage 3B NSCLC.
78.2% of patients expired during follow-up. Median OS was 14 months. 1-year, 2-year,
and 5-year OS was 56.5%, 34.6% and 13.9%, respectively. Univariate Cox regression
analysis showed no significant difference in OS on the basis of age, gender, histology,
ln(TLGwb), or ln(SUVmaxwb). ln(MTVwb) was positively associated with OS [hazard ratio
(HR) of 1.23, p = 0.037]. This association persisted on multivariate Cox regression analysis
(HR 1.28, p = 0.043), with adjustments for age, gender, treatment and tumor histology.
External validation with 44 patients from center B confirmed increasing MTVwb was
associated significantly worse OS. An MTVwb cut-off point of 85.6 mL significantly
stratified Stage 3B NSCLC patient prognosis.
Conclusion: MTVwb is a prognostic marker for OS in patients with Stage 3B NSCLC,
independent of age, gender, treatment, and tumor histology.
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Lung cancer is the leading cause of cancer death within the United States (Siegel et al.,
2016). The TNM staging system developed by the American Joint Committee on
Cancer (AJCC)/Union for International Cancer Control (UICC) is the primary means
for classifying patient disease status and predicting patient prognosis, with the most
recent 8th edition recently introduced by the International Association for the Study of
Lung Cancer (IASLC) (Detterbeck et al., 2016; Asamura et al., 2015; Rami-Porta et al.,
2015; Goldstraw et al., 2016). Stage 3B Non-small Cell Lung Cancer (NSCLC) now
comprises patients without distant metastases (M0) who have stage T3 or T4 primary
disease, with ipsilateral mediastinal and/or subcarinal nodal metastases (N2), as well as
patients with T1 or T2 primary disease with metastases in scalene, supraclavicular,
contralateral mediastinal or contralateral hilar lymph nodes (N3). In other words, Stage
3B encompasses a wide range of primary tumor burden, including patients with
primary tumors ranging from <1 cm (T1a) to ≥7 cm (T4) in greatest dimension and
N0 to N3 nodal metastases.
For patients with locally advanced lung cancer, fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) enables detection of CT-occult,
metabolically active tumor. Maximum standardized uptake value (SUVmax) is an estab-
lished measurement of maximal tumor metabolic activity and facilitates identification
of tumor metastases, but it fails to take into account total tumor abundance/burden.
Quantitative FDG measurements, namely the amount of whole body metabolic tumor
volume (MTVwb) and total lesion glycolysis (TLGwb), may be used to quantify
both total tumor burden and metabolic activity. These parameters have been found
to be associated with OS for both surgical and non-surgical NSCLC patients, after
adjusting for clinical stage (Liao et al., 2012a; Zhang et al., 2013a; Zhang et al.,
2013b). These PET/CT metrics have yet to be evaluated for Stage 3B NSCLC patients
(Ohri et al., 2015).
Patients with Stage 3B NSCLC are rarely surgical candidates due to mediastinal inva-
sion or extensive nodal disease, and are routinely treated with combined radiation and
chemotherapy, though options are constantly evolving to cater to a more individualized
patient-centered therapeutic approach (Rocco et al., 2016). The overall survival (OS) of
Stage 3B NSCLC patients at 2 and 5 years is 44% and 26%, respectively (Goldstraw
et al., 2016). If we can identify additional prognostic markers for these patients, we may
be able to better stratify Stage 3B NSCLC patients, and determine who is more likely to
benefit from more aggressive therapy.
Here we aimed to evaluate the prognostic value of MTVwb, TLGwb, and SUV-
maxwb, on baseline FDG PET/CT in patients with Stage 3B NSCLC.Materials and methods
This Health Insurance Portability and Accountability Act compliant retrospective study
received institutional review board approval. The need for informed consent was waived.Patient cohort
Utilizing a retrospective search of our health information system, patients were
included if they met both of the following inclusion criteria: a. diagnosed with Stage 3B
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received baseline staging PET/CT between February 2004 and Dec 2014. Patients were
excluded if they either: 1. received prior lung cancer treatment, including chemother-
apy, radiation, or surgery; or 2. had a second primary cancer diagnosed from 5 years
before to 2 months after the FDG PET/CT scan conducted for NSCLC diagnosis and
staging. 110 consecutive patients were identified from center A and served as the
training set. The external validation set included 44 patients managed and imaged at in-
stitution B from 2008 to 2014. These patients received a FDG PET/CT within 3 months
of starting radiation therapy.
Patient demographics, clinical information, and follow-up were collected from the
health information system. Patients were censored at date of last contact.PET/CT acquisition
Imaging was performed on a Siemens mCT scanner (Siemens Healthcare, Knoxville,
Tenn) or Reveal HD scanner (CTI, Knoxville, Tenn). All patients fasted for a minimum
of 4 h prior to imaging, confirmed by fingerstick serum blood glucose levels <200 mg/dl.
Patients were injected with 370-555 MBq 18F–FDG. At center A (the training dataset),
whole body PET/CT imaging was acquired approximately 90 min later. At center B (the
validation dataset), patients were scanned approximately 60 min later. Concomitant low-
dose non-contrast or diagnostic CT extending from the skull base to thighs was
performed for anatomic localization and attenuation correction.
PET/CT tumor volume, SUVmaxwb, MTVwb, and TLGwb were measured using the
PET Edge tool of MIMvista software as illustrated in Fig. 1, using semi-automated
tumor segmentation, as previously described (Liao et al., 2012a).
Briefly, SUVmax for each tumor lesion was defined as: decayed corrected activity=tissue volumeinjected dose=injected weight .
SUVmaxwb was taken to be the largest SUVmax among all tumor lesions identified on
baseline staging PET/CT. MTVwb was defined as the total segmented volume of all
FDG-avid tumors in the body. TLG for a single tumor lesion is the product of MTV
and the average SUV for the lesion. TLGwb was calculated as the sum of the TLGs of
all segmented tumor.Statistical analysis
Statistical analyses were performed using Stata Software version 14. OS was considered
the primary endpoint and defined as the time from baseline PET/CT to time of any
cause mortality. Analysis was conducted using natural-logarithm transformed values of
the PET parameters [(ln(MTVwb), ln(TLGwb), and ln(SUVmaxwb)] in order to achieve
a near-normal distribution of independent variables. Univariate and multivariate
analyses were performed with Cox proportional hazard regression models to test for an
association with the primary end point, OS. P-value of <0.05 from a two-tailed test was
considered significant. Survival curves were plotted using the Kaplan-Meier method.Results
Model fitting
The model was fitted using the training dataset of 110 patients with Stage 3B NSCLC
(41% adenocarcinoma; 32% squamous cell; 27% other histologic sub-type) who met the
Fig. 1 Whole-body PET images of a 59 year-old male with newly diagnosed squamous cell carcinoma,
stage IIIB (T4N2M0). This study was performed for initial staging. Colored regions of interest (ROIs) show the
tumor contours. The MTVwb in mL is the sum of tumor volumes in all ROIs. Axial image (a), sagittal image
(b), coronal image (c) and maximal intensity projection image (d)
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patient age was 67.3 (range 31.4–83.9) years. There were 47 Caucasian patients, 60
African American patients and 3 Asian patients. The majority of patients (69%) were
managed non-surgically (with chemotherapy and/or radiation), while 22% received
surgical treatment, and 9% did not treatment. 86/110 patients expired during
follow-up. The median OS was 14 months. 1-year, 2-year, and 5-year OS was
56.5%, 34.6% and 13.9%, respectively. The median follow-up among survivors was
26.0 months (inter-quartile range 13.6 to 57.1 months).
Univariate Cox regression analysis showed no significant difference in OS on the
basis of age, gender, or histology (Table 2). Surgical treatment (24/110 patients) was
associated with improved OS, as compared to the no treatment and non-surgical
treatment groups. Some of the PET/CT variables, ln(TLGWB) and ln(SUVWB), were not
associated with OS.
However, ln(MTVwb) was positively associated with OS, with a hazard ratio (HR) of
1.23 with 95% confidence interval (95% CI) of 1.01–1.49, (p = 0.037). This association
persisted on multivariate Cox regression analysis with a HR of 1.28 (95% CI =1.01–
1.64, p = 0.043), after adjustment for age, gender, treatment and tumor histology
(Table 3).
The training dataset was segmented by the median MTVwb of 85.6 mL, Kaplan-
Meier survival curves (Fig. 2) demonstrate decreased OS among patients with MTVwb
greater than or equal to the median, when compared to those patients with MTVwb
less than the median (p = 0.021). The median OS was 9.5 months in patients with
MTVwb greater than or equal to the median, while the median OS was 17.3 months in
patients with MTVwb less than the median.
Table 1 Characteristics of patients from the University of Chicago














Squamous cell 35 32%
Other typesa 30 27%
Age (Median and range, years) 67.3(31.4–83.9)
>65 44 40%
<65 66 60%
MTVwb (Median and range, ml) 85.6(3.2–1261.4)
TLGwb (Median and range, ml) 485.5(12.1–4921.0)
SUVmaxwb (Median and range) 13.07(3.5–42.9)
MTVwb whole-body metabolic tumor volume, SUVmaxwb whole-body maximum standardized uptake value, TLGwb
whole-body total lesion glycolysis
aOther histological subtypes including large cell (n = 7), NSCLC not otherwise specified (n = 21) and neuroendocrine
tumor (n = 2)
Table 2 Univariate Cox regression analyses
Hazard ratio 95% CI P-value
Age (per 1 year increase) 1.02 0 .99 -1.034 0.171
Gender
Female Reference
Male 1.19 0.78–1.83 0.419
Histology
Adenocarcinoma Reference
Squamous 1.37 0.83–2.26 0.218
other types 1.33 0.78 2.27 0.303
Treatment
Non-surgical (n = 76) Reference
Surgical (n = 24) 0.4 0.22 -0.71 0.002
No treatment (n = 10) 0.99 0.47 -2.1 0.986
ln(MTVwb) 1.23 1.01–1.49 0.037
ln(TLGwb) 1.13 0.95–1.34 0.175
In(SUVmaxwb) 0.91 0.57–1.43 0.67
Note: ln(MTVwb), ln(TLGwb) and ln(SUVmaxwb) are continuous variables. ln = natural logarithmic transformation
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Table 3 Multivariate Cox regression analyses of whole cohort
Variables Hazard ratio 95% CI P-value
ln(MTVwb) 1.28 1.01–1.64 0.043
Treatment
Non-surgical Reference
Surgical 0.41 0.22–0.76 0.004
No treatment 1.34 0.59–3.02 0.48
Additional adjustments were made for age, gender, treatment and tumor histology
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To validate the model, a separate analysis was performed using a dataset of 44 patients
who were imaged and managed from medical center B. These 44 patients received
radiation-based treatment. The median OS was 20 months and 1-year, 2-year, and
5-year OS was 60%, 45% and 38%, respectively. 24/44 patients (55%) expired during
follow-up. The median follow-up among survivors was 30.7 months (inter-quartile
range 12.7 o 49.1 months).
With a univariate Cox regression model, there was significant positive correlation of
ln(MTVwb) with OS, HR of 1.83 (95% CI = 1.14–2.94, p = 0.012). For 7 of 44 patients,
the SUVmax and TLGwb were not available due to missing accurate weight informa-
tion during PET/CT acquisition. Univariate Cox regression analysis in the remaining 37
patients demonstrated no statistically significant association of ln(TLGwb) (HR = 1.37,
95% CI = 0.94–2.00, p = 0.1) and ln(SUVmaxwb) (HR = 1.30, 95% CI = 0.53–3.17,
p = 0.57) with OS. After adjusting for tumor histology, there remained significant posi-
tive correlation with ln(MTVwb) and OS, with HR of 1.78 (95% CI = 1.01–2.90,
p = 0.02). The results provided further evidence for the prognostic value of
ln(MTVwb). Kaplan-Meier survival curves with groups defined by the median MTVwb
from the training set (85.6 mL) further demonstrated significantly lower OS among
patients with MTVwb ≥85.6 mL, when compared to those with MTVwb <85.6 mLFig. 2 Kaplan-Meier overall survival curves of the training dataset of 110 patients with TNM Stage 3B
NSCLC, stratified by the median MTVwb of 85.6 mL. The dashed line indicates patient group with
MTVwb greater than or equal to 85.6 ml with median OS of 9.5 months. The solid line indicates
patient group with MTVwb less than 85.6 ml with median OS of 17.3 months. The difference is
statistically significant with p = 0.02
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patients with MTVwb <85.6 mL, the median OS could not be determined because
more than 50% of patients were alive at the last follow-up (median follow-up of
30.7 months).
Discussion
Quantitative PET/CT parameters are increasingly used to better stratify patients with
cancer. Multiple studies have evaluated the association of primary tumor and whole
body MTV, TLG, and SUVmax with respect to OS, though this has yet to be evaluated
for Stage 3B NSCLC (8th edition TNM classification) (Liao et al., 2012a; Zhang et al.,
2013a; Zhang et al., 2013b; Ohri et al., 2015; Liao et al., 2012b; Chung et al., 2014; Im
et al., 2015; Hyun et al., 2013; Hyun et al., 2014; Carvalho et al., 2013; Kim et al., 2012;
Abelson et al., 2012; Satoh et al., 2014; Winther-Larsen et al., 2016; Yoo et al., 2012;
Zhu et al., 2016; Vu et al., 2013; Lee et al., 2007). We sought to better delineate
prognosis among patients with Stage 3B NSCLC by utilizing MTVwb, SUVmaxwb, and
TLGwb.
Among patients with Stage 3B NSCLC, greater MTVwb was associated with shorter
OS, independent of age, sex, and histology. This was further validated by an external
dataset of 44 patients treated with radiation-based treatment at outside hospitals. Other
studies have shown that OS significantly decreases with every 1 cm increase in primary
tumor burden and with increasing number and extent of nodal metastases, which
prompted recent changes to the TNM classification (Asamura et al., 2015; Goldstraw
et al., 2016). Thus, it is not surprising that quantitative PET/CT measures of whole
body tumor burden are similarly associated with OS.
Here we did not find a significant association between SUVmaxwb or TLGwb and
OS in patients with Stage 3B NSCLC. SUVmaxwb is a maximum single voxel measure-
ment, so it may not be representative of the entire disease process. Additionally, SUV-
maxwb is not representative of the total extent of tumor burden. Though TLGwbFig. 3 Kaplan-Meier overall survival curves of the validation dataset of 44 patients with TNM stage 3B
NSCLC, stratified by the median MTVwb of the training dataset, 85.6 mL. The dashed line represents the
patient group with MTVwb ≥85.6 ml with median OS of 13.9 months. The solid line represents the patient
group with MTVwb <85.6 ml with median OS not reached during follow-up period. The groups were
significantly different with p = 0.03
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sample of patients with Stage 3B NSCLC, despite the estimated HR of 1.13. The lack of
statistical significance is most likely due to the small sample size in this study, as
opposed to a true lack of association with survival.
Among the Stage 3B NSCLC patients in the training cohort, the 2-year and 5-year
OS was 34.6% and 13.9%, lower than the survival observed in the IASLC database (44%
and 26%, respectively) (Goldstraw et al., 2016). However, our validation dataset had 2-
and 5-year survival of 45%, 38%, which is more similar to the IASLC database. One
explanation for the difference in OS may be related to socioeconomic status: Center A
serves a predominantly low-income neighborhood, a factor that has been previously
associated with worse OS (Aldrich et al., 2013). Furthermore, the training dataset
included 10 patients who had no treatment, which is likely to lower OS.
The training dataset had a significantly higher proportion of African American pa-
tients (55%) than other studies, like the 1996–2007 Florida Cancer Data System registry
of 98,541 patients with NSCLC, which was only 7.4% African American (Tannenbaum
et al., 2014). Although our study included a disproportionate number of African
Americans compared to both other registries and the national population, prior work
by Aldrich et al., has shown that lung cancer survival is independent of race, when
adjusting for stage and socioeconomic status (Aldrich et al., 2013).Limitations
Due to the retrospective design of this study, it was not possible to control the type of
surgery, chemotherapy or radiation that patients received. Treatment for each patient was
determined at the discretion of the surgeon and oncologist and, ultimately, by the patient.
In addition, PET/CT has limited sensitivity to detect lesions which are less than 1 cm in
diameter or which have low metabolic uptake, likely resulting in a slight under measure-
ment of MTVwb and TLGwb. Since patients in the validation dataset were exclusively
treated with radiation-based treatment, and the significant association between OS and
MTVwb persists, this strongly suggests the robust prognostic value of MTVwb.
In summary, among patients with Stage 3B NSCLC increasing MTVwb measured on
baseline FDG PET/CT is associated with worse OS in both univariate and multivariate
cox regression analysis, as seen in both the training and validation datasets. Currently,
PET/CT volumetric parameters do not affect clinical management, but hopefully the
developing knowledge regarding the values of these measurements may allow more tar-
geted treatment for patients with more or less aggressive disease. Regardless, identifying
which patients are more likely to survive to 2 or 5 years may be extremely valuable to
patients, who may be planning the final months or years of their life.Conclusion
MTVwb is a prognostic marker for OS in patients with Stage 3B NSCLC, independent
of age, gender, treatment, and tumor histology.
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